HOME >> BIOLOGY >> NEWS
MIT model could predict cells' response to drugs

CAMBRIDGE, MA, July 27MIT researchers have developed a model that could predict how cells will respond to targeted drug therapies. Models based on this approach could help doctors make better treatment choices for individual patients, who often respond differently to the same drug, and could help drug developers identify the ideal compounds on which to focus their research.

In addition, the model could help test the effectiveness of drugs for a wide range of diseases, including various kinds of cancer, arthritis and immune system disorders, according to Douglas Lauffenburger, MIT professor of biological engineering and head of the department. Lauffenburger is senior author of a paper on the new model that will appear in the Aug. 2 issue of Nature.

The model is based on similarities in the signaling pathways cells use to process information. Those pathways translate cells' environmental stimuli, such as hormones, drugs or other molecules, into action.

"Cells undertake behavioral functions-proliferation, differentiation, death-in response to stimuli in their environment," said Lauffenburger. "The signaling pathways are the biomolecular circuits that process that information from the environment and regulate the mechanisms that execute the behavorial functions."

The pathways work via a series of signals in which proteins, known as kinases, activate other cell machinery to achieve a specific result, e.g., expression of certain genes, or actions of cytoskeletal proteins. While the same stimuli can produce diverse responses in different types of cells, the researchers believe they can use the same core pathways to achieve various end results.

Lauffenburger compared a cell's strategy to playing a piano: Just as there are 88 keys that can be played in a vast number of combinations to produce different melodies, cells can use their multiple pathways together in many different combinations to produce different behaviors.'"/>

Contact: Patti Richards
prichards@mit.edu
617-253-8923
Massachusetts Institute of Technology
30-Jul-2007


Page: 1 2

Related biology news :

1. Huntingtons disease study shows animal models on target
2. Stem cell therapy rescues motor neurons in ALS model
3. Drug protects brain cells in Huntingtons disease model, researchers find
4. New model for autism suggests women carry the disorder and explains age as a risk factor
5. New treatment model for HIV
6. A first-principles model of early evolution
7. Virginia Tech researchers to study poplar tree as model biomass crop
8. Scripps research scientists show protein accelerates breast cancer progression in animal models
9. Better chemistry through living models
10. Gene therapy delivery of nerve growth factors reverses erectile dysfunction in animal model
11. New mouse model closely mimics human cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MIT model could predict cells response drugs

(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... , May 21, 2013 ... Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services ... Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, ... in 2011 and is expected to grow at a ... an estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 2013 Revolutionary Science, the manufacturer of ... announced today that they have expanded their colony counter ... IncuCount, IntelliCount, InCount and ImpressCount. These affordable colony ... useful in food microbiology and pharmaceutical manufacturing. , The ... A bright white enclosure with jet black accents ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2
Cached News: